Alkem Lab
Alkem Lab Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 4 strong
Not discussed on this call: order book.
The short version
International Business:** Sustainable double-digit growth expected, driven by smaller markets like Germany (35-40% growth), Chile, and Australia. India business growth is expected around 12% for the full year, slightly better than previous guidance.
From Alkem Lab's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- **International Business:** Sustainable double-digit growth expected, driven by smaller markets like Germany (35-40% growth), Chile, and Australia. U.S. business remains flat to high single-digit growth due to pricing pressure and currency effects.
- **U.S. Market:** Anticipated growth in high single to mid-single digits in FY27, helped by currency benefits. No major volume expansion seen in last 12-24 months.
- **India Business:** Branded formulations expected to grow around 12%; Trade Generics growth slower—late single digits anticipated with disciplined execution.
- **CDMO Business:** Revenue of USD 30 million targeted by FY28; breakeven expected when such revenue is achieved.
- **Overall:** India market expected to outperform industry by 100 basis points; chronic and acute segments showing sustained growth; continued focus on execution and disciplined growth.
Profitability & Margins
See what Alkem Lab said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company currently has reasonable capacity at its CDMO facility in the U.S., with some specialized technology; however, it is relatively small.
- Future capex will be required at the CDMO facility to ramp up production and achieve economies of scale, but this is not expected to happen in the current fiscal year.
- No plans for acquisitions in the orthopedics or MedTech segment at present; focus is on ramping up existing operations.
- The Daman plant has received an OAI status, and corrective actions are underway; no expected impact on capex specifics mentioned.
- Overall, capex related to CDMO expansion is planned but timed based on business growth and scale requirements.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alkem Lab said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The exact number of pending ANDAs (Abbreviated New Drug Applications) for the Daman facility is not specified; the management mentioned they would provide this information later.
- For the U.S. CDMO (Contract Development and Manufacturing Organization) business, the revenue breakeven is expected at an annualized USD 25-30 million run rate.
- The CDMO business has a decent project pipeline but the sales cycle is long and lumpy, dependent on client funding and clinical trial progress.
- The company anticipates CDMO revenues to start rising in FY27 and FY28, with the USD 30 million revenue target expected by FY28.
- The Daman plant faced an OAI (Official Action Indicated) status but continues supplying products without interruption, with resolution expected in 6-12 months.
- 45% of U.S. revenues come from the Daman facility.
Alkem Lab — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.6K Cr, net profit ₹251 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alkem Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Alkem Lab Q1 FY27 results?
International Business:** Sustainable double-digit growth expected, driven by smaller markets like Germany (35-40% growth), Chile, and Australia. India business growth is expected around 12% for the full year, slightly better than previous guidance.
What is Alkem Lab share price analysis?
Alkem Lab currently shows a below-average growth signal. The stock trades at a P/E of 28.4 with a market cap of ₹64,565 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alkem Lab planning capital expenditure?
The company currently has reasonable capacity at its CDMO facility in the U.S., with some specialized technology; however, it is relatively small.
Keep Alkem Lab on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.